Studying MASLD in Breast and Colorectal Cancer Survivors Using Non-Invasive Imaging and Blood Tests to Detect Liver Disease

What this Trial Is About

Metabolic-associated steatotic liver disease MASLD, also known as non-alcoholic fatty liver disease, happens when fat builds up in the liver due to problems with metabolism, such as obesity, diabetes, or high blood pressure. MASLD can range from mild to severe, with advanced cases causing liver inflammation, scarring, and potentially liver failure. Cancer survivors are at higher risk because of changes in metabolism, lifestyle, and cancer treatments, yet MASLD is often underdiagnosed in this group. This observational study by the University of Bern uses non-invasive methods like vibration-controlled transient elastography VCTE or FibroScan and Magnetic Resonance Imaging MRI to check for signs of fibrotic MASLD in breast or colorectal cancer survivors. Participants may also have blood tests to calculate scores indicating the risk of advanced MASLD. If the main results are unclear, participants might join an MRI sub-study for further evaluation. Participants will be assessed at enrollment and three months later with measures including liver stiffness, fat content, body measurements, cancer history, and treatment details. The study aims to improve early detection and monitoring of MASLD in cancer survivors using safer, less painful tests than liver biopsy. The findings could help develop better guidelines and care for those at risk of liver problems after cancer.

The Development of MASLD Among Survivors of Breast or Colorectal Cancer